ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 929

Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study

Stanley Cohen1, Katie Tuckwell 2, Rebecca Kunder 2, Tamiko Katsumoto 3, Rui Zhao 2, Alberto Berman 4, Nemanja Damjanov 5, Dmytro Fedkov 6, Slawomir Jeka 7 and Mark Genovese 3, 1Metroplex Clinical Research Center, Dallas, TX, 2Genentech, Inc., South San Francisco, CA, 3Stanford University, Stanford, CA, 4Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, 5Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, 6Bohomolets National Medical University, Kyiv, Ukraine, 7University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: BTK, clinical trials, rheumatoid arthritis (RA) and small molecules, Tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: 3S109: RA – Treatments II: Novel Treatments for RA (927–932)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an orally administered, highly selective, non-covalent, and reversible small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK).1 We report the efficacy and safety of FEN compared with placebo (PBO) in combination with background methotrexate (MTX) in patients with rheumatoid arthritis (RA) and an inadequate response to tumor necrosis factor (TNF-IR), identified as a population with existing unmet medical need.

Methods: This multicenter, randomized, double-blind Phase 2 study included two cohorts of patients with moderate-to-severe RA: cohort 1 (MTX-IR patients) and cohort 2 (TNF-IR patients). Primary (cohort 1) and key secondary (cohorts 1 and 2) endpoints were a 50% improvement in the American College of Rheumatology scores (ACR50) at Week 12, with pre-specified alpha of 0.2. Patients in cohort 2 (TNF-IR) were randomized to PBO and to FEN 200 mg BID arms for 12 weeks with the continuation of background MTX dose; the safety and efficacy results for this cohort are reported here (cohort 1 data has been reported previously2).

Results: Demographics and disease characteristics for the TNF-IR cohort were balanced in the PBO (n=49) and FEN (n=49) arms with mean age of 55 and 51 years, respectively, and 76% female patients/arm. Median duration of RA disease was 8.7 years (PBO) and 7.2 years (FEN). The mean baseline doses for MTX were 16.6 mg (PBO) and 15.7 mg (FEN). Corticosteroid mean doses were 8.3 and 7.5 mg prednisone-equivalents in the 33% and 39% of patients using corticosteroids in the PBO and FEN arms at baseline, respectively. Baseline mean values for DAS28-CRP and HAQ-DI were similar (6.0 and 5.9, and 1.76 and 1.45, respectively) for PBO and FEN arms. The majority of patients in the PBO (90%) and FEN (98%) arms completed the 12-week study. ACR20/50/70 responses (Table 1) were greater for FEN versus PBO and generally increased over time, with plateau of ACR50 after W8 for all patients. ACR50 response at W12 was greater for FEN (25% vs 12%, p-value=0.07 [pre-specified type-1 error rate=0.20 two sided]). At W12, DAS28-CRP decreased by -1.43 (PBO) and -2.26 (FEN) from baseline. More patients in the PBO arm (45%) than in the FEN arm (22%) reported at least one AE; no serious AEs were reported. There were 37 AEs in the PBO arm and 22 AEs in the FEN arm (including one case of herpes zoster), with one AE (worsening RA) leading to treatment withdrawal in the PBO group. No deaths or malignancies were reported. There were no clinically significant changes in hematology or immunoglobulin parameters. In two patients treated with FEN, Grade 3 chemistry abnormalities were observed (low phosphorous, high uric acid). No Grade 4 or 5 abnormalities were reported. Although no Grade 3 creatinine elevations were observed, there was an increased mean change from baseline in creatinine in the FEN arm (5.1 µmol/L) in comparison to PBO arm (-0.4 µmol/L) at W12.

Conclusion: FEN demonstrated higher efficacy rates across disease activity measures vs. PBO at W12 in the TNF-IR population. The safety profile of FEN in this population is acceptable.


Table 1


Disclosure: S. Cohen, AbbVie, 2, 5, Abbvie, 5, Amgen, 5, Amgen Inc., 2, 5, AstraZeneca, 2, 5, Biogen-IDEC, 2, 5, Bristol Meyer Squibb, 2, 5, Genentech, 2, 5, Janssen, 2, 5, Lilly, 2, 5, Merck, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, 5; K. Tuckwell, Genentech/Roche, 3, 4; R. Kunder, Genentech/Roche, 3, 4; T. Katsumoto, Abbvie, 5, Genentech/Roche, 4, 5, Principia Biopharma, 5; R. Zhao, Genentech/Roche, 3, 4; A. Berman, AbbVie, 2, Abbvie, 2, Amgen, 2, Bristol Myers Squibb, 2, Bristol-Myers Squibb, 2, Eli Lilly, 2, Genentech/Roche, 2, Janssen, 2, Lilly, 2, Merck Serono, 2, MSD, 2, Pfizer, 2, Roche, 2, Sanofi, 2, Servier, 2; N. Damjanov, Abbvie, 2, 5, AbbVie, 2, 5, 9, Gedeon Richter, 2, 5, 9, Merck, 2, 5, 9, Merck Serono, 2, 5, Novartis, 2, 5, 9, Pfizer, 2, 5, 9, Roche, 2, 5, 9; D. Fedkov, Abbvie, 2, 5, Janssen, 5, Laboratoires Expanscience, 2, 5, ProPharma, 2, 5, MSD, 2, 5; S. Jeka, None; M. Genovese, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Inc., 9, Astellas, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, EMD Merck Serono, 2, 5, Galapagos, 2, 5, Galapagos NV, 2, 5, 9, Genentech/Roche, 2, 5, Gilead, 2, 5, Gilead Science, 9, Gilead Sciences, Inc., 2, 5, 9, GSK, 5, Lilly, 2, 5, 9, Novartis, 2, 5, Pfizer, 2, 5, 9, Pfizer Inc, 2, 5, Pfizer, Inc., 9, Pzier, 9, RPharm, 5, Sanofi Genzyme, 2, 5, Vertex, 2, 5.

To cite this abstract in AMA style:

Cohen S, Tuckwell K, Kunder R, Katsumoto T, Zhao R, Berman A, Damjanov N, Fedkov D, Jeka S, Genovese M. Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-fenebrutinib-a-btk-inhibitor-compared-to-placebo-in-rheumatoid-arthritis-patients-with-active-disease-despite-tnf-inhibitor-treatment-randomized-double-blind-phase-2-study/. Accessed January 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-fenebrutinib-a-btk-inhibitor-compared-to-placebo-in-rheumatoid-arthritis-patients-with-active-disease-despite-tnf-inhibitor-treatment-randomized-double-blind-phase-2-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.